Comparison of bronchial and nasal allergen provocation in children and adolescents with bronchial asthma and house dust mite sensitization

Fischl, A; Eckrich, Jonas; Passlack, Vanessa; Klenke, Sara-Kristin; Hartmann, Desireé; Herrmann, Eva; Schulze, Johannes; Zielen, Stefan

doi:10.1111/pai.13147

Cited by 12 publications

(12 citation statements)

References 37 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 Its pathophysiology, which involves various cells and inflammatory factors, 2 is mainly characterized by airway hyperresponsiveness, inflammation, and smooth muscle spasm, as well as goblet cell proliferation and increased mucus secretion, 3,4 It was estimated that approximately 300 million people worldwide experience bronchial asthma 5 ; moreover, along with the acceleration of urbanization in our country, the incidence of bronchial asthma is increasing annually. 6 Relevant research has indicated that bronchial asthma has the highest incidence rate among all pediatric chronic diseases 7 ; repeated acute asthmatic crises can severely affect children’s quality of life, ultimately threatening their health and substantially burdening their families and the society. At present, clinical treatment is mainly based on pharmacological control, which can hardly cure asthma.…”

Section: Introductionmentioning

confidence: 99%

RETRACTED: Role of miR-27a in the regulation of cellular function via the inhibition of MAP2K4 in patients with asthma

Yang

Wang

Luo³

et al. 2021

Hum Exp Toxicol

View full text Add to dashboard Cite

Asthma is a respiratory disease with a clinically high incidence, and repeated attacks of asthma severely affect the quality of life and even pose a threat to health, leading to severe burdens on families and even the society. A thorough understanding of the pathogenesis of asthma is essential for the prevention and treatment of asthma. This study aimed to examine the effect of the microRNA miR-27a on asthma and its relationship with mitogen activated protein kinase 4 (MAP2K4). Patients with asthma admitted to our hospital from August 2016 to August 2018 and healthy participants in the same period were included in this prospective analysis. The mRNA expression levels of miR-27a and MAP2K4 in peripheral blood were determined. Airway smooth muscle cells (ASMCs) were used to study the effects of miR-27a and MAP2K4 on cell biological behavior. The relationship between miR-27a and MAP2K4 was verified using dual-luciferase reporter assay. miR-27a expression was increased and MAP2K4 mRNA expression was decreased in asthma (P < 0.05). Increasing miR-27a expression and inhibiting MAP2K4 expression could enhance the activity of ASMCs, whereas inhibiting miR-27a expression and increasing MAP2K4 expression had the opposite effect (P < 0.05). Dual-luciferase reporter assay results showed that the fluorescence activity of MAP2K4-wild type was inhibited by increased miR-27a expression (P < 0.05). miR-27a promotes the proliferation and invasion of ASMCs by targeting MAP2K4 and is involved in the occurrence of asthma.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED: Role of miR-27a in the regulation of cellular function via the inhibition of MAP2K4 in patients with asthma

Yang

Wang

Luo³

et al. 2021

Hum Exp Toxicol

View full text Add to dashboard Cite

show abstract

“…Of note, 83-89% of atopic asthmatics with rhinitis who tested positive to the nasal challenge with HDM have positive BAC results. 44,93 The NAC is a safe and reproducible technique 94,95 with a validated methodology 56 and defined cut-off points for positivity. 96 Moreover, challenge protocols are considerably shorter than those of BAC.…”

Section: Prop Osal For Integ R Ating Bac In the C Are Pathways Of A S...mentioning

confidence: 99%

“…In this regard, NAC could be a useful tool to phenotype the inflammatory disease affecting the airways regardless of its organ‐specific manifestations (conjunctivitis, rhinitis and asthma). Of note, 83–89% of atopic asthmatics with rhinitis who tested positive to the nasal challenge with HDM have positive BAC results 44,93 . The NAC is a safe and reproducible technique 94,95 with a validated methodology 56 and defined cut‐off points for positivity 96 .…”

Section: Proposal For Integrating Bac In the Care Pathways Of Asthma ...mentioning

confidence: 99%

EAACI position paper on the clinical use of the bronchial allergen challenge: Unmet needs and research priorities

Agache

Antolín‐Amérigo

Blay

et al. 2022

Allergy

Self Cite

View full text Add to dashboard Cite

Allergic asthma (AA) is a common asthma phenotype, and its diagnosis requires both the demonstration of IgE‐sensitization to aeroallergens and the causative role of this sensitization as a major driver of asthma symptoms. Therefore, a bronchial allergen challenge (BAC) would be occasionally required to identify AA patients among atopic asthmatics. Nevertheless, BAC is usually considered a research tool only, with existing protocols being tailored to mild asthmatics and research needs (eg long washout period for inhaled corticosteroids). Consequently, existing BAC protocols are not designed to be performed in moderate‐to‐severe asthmatics or in clinical practice. The correct diagnosis of AA might help select patients for immunomodulatory therapies. Allergen sublingual immunotherapy is now registered and recommended for controlled or partially controlled patients with house dust mite‐driven AA and with FEV1 ≥ 70%. Allergen avoidance is costly and difficult to implement for the management of AA, so the proper selection of patients is also beneficial. In this position paper, the EAACI Task Force proposes a methodology for clinical BAC that would need to be validated in future studies. The clinical implementation of BAC could ultimately translate into a better phenotyping of asthmatics in real life, and into a more accurate selection of patients for long‐term and costly management pathways.

show abstract

“…The NPT was performed according to our laboratory's standard as recently described in more detail and interpreted in concordance with international standards. 4,5,20,21 Before starting the NPT, we made sure that no patient had used any treatment for rhinitis before. After nasal secretion collection, a NPT with HDM allergen was performed.…”

Section: Nasal Provocation Testmentioning

confidence: 99%

Nasal IgE in subjects with allergic and non-allergic rhinitis

Eckrich

Hinkel

Fischl

et al. 2020

World Allergy Organization Journal

Self Cite

View full text Add to dashboard Cite

Purpose:The prevalence of "ocal allergic rhinitis" within individuals suffering from perennial rhinitis remains uncertain, and patients usually are diagnosed with non-allergic rhinitis. The aim of this study was to evaluate the prevalence of a potential "local allergic rhinitis" in subjects suffering from non-allergic rhinitis in a non-selected group of young students.Methods: 131 students (age 25.0 AE 5.1 years) with a possible allergic rhinitis and 25 non-allergic controls without rhinitis symptoms (age 22.0 AE 2.0 years) were recruited by public postings. 97 of 131 students with rhinitis were tested positive (!3 mm) to prick testing with 17 frequent allergens at visit 1. Twenty-four 24 subjects with a house dust mite allergy, 21 subjects with a non-allergic rhinitis, and 18 non-allergic controls were further investigated at visit 2. Blood samples were taken, and nasal secretion was examined. In addition, all groups performed a nasal provocation test with house dust mite (HDM). Results:In serum and nasal secretion, total IgE and house dust mite specific IgE significantly differed between HDM positive subjects and controls. However, no differences between nonallergic subjects and control subjects were quantifiable. Neither a nasal provocation test nor a nasal IgE to HDM allergens showed a measurable positive response in any of the non-allergic rhinitis subjects as well as the healthy controls, whilst being positive in 13 subjects with HDM allergy.Conclusions: Nasal IgE is present in subjects with HDM allergy, but not in non-allergic rhinitis. In the investigated non-selected population, exclusive local production of IgE is absent. By implication, therefore, our findings challenge the emerging concept of local allergic rhinitis. Study identifier at ClinicalTrials.gov: NCT 02810535.

show abstract

Comparison of bronchial and nasal allergen provocation in children and adolescents with bronchial asthma and house dust mite sensitization

Cited by 12 publications

References 37 publications

RETRACTED: Role of miR-27a in the regulation of cellular function via the inhibition of MAP2K4 in patients with asthma

RETRACTED: Role of miR-27a in the regulation of cellular function via the inhibition of MAP2K4 in patients with asthma

EAACI position paper on the clinical use of the bronchial allergen challenge: Unmet needs and research priorities

Nasal IgE in subjects with allergic and non-allergic rhinitis

Contact Info

Product

Resources

About